Description of the medicine: Glipizide (Glipizide)
GLIPIZIDE (Glipizide). 1-Cyclohexyl-3- [[para-2- (5-methylpyrazinecarboxamide) ethyl] phenyl] sulfonyl] urea.
Synonyms: Minidiab, Glibenese, Glucotrol, Glydiazinamide, Melizid, Menodiab, Mindiab, Minibetic, Minidiab, Minodiab.
The chemical structure and action is very close to glibenclamide.
It is well absorbed. The maximum concentration in the blood is observed 1 to 2 hours after administration. It has a short half-life (3-4 hours at 5-7 hours for glibenclamide and 30-40 hours for chlorpropamide). It is quickly excreted from the body, and therefore the risk of cumulation is reduced.
Indications for use are the same as for other antidiabetic sulfonylurea derivatives (type II diabetes).
The initial dose is usually 2, 5 - 5 mg (1/2 - 1 tablet) per day, then increase the dose by 1/2 - 1 tablet until the optimal maintenance dose is reached.
The maximum dose is 30 mg (6 tablets) per day. Small doses are taken once a day, doses over 15 mg in 2 to 3 doses.
Contraindications and precautions are the same as when using glibenclamide, butamide.
Release form: tablets of 0.005 g (5 mg) in a package of 30 pieces.